共 47 条
- [31] Effect of PD1/PD-L1 checkpoint blockade on efficacy of anti-GD2 antibody ch14.18/CHO in neuroblastoma.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Lode, Holger N.Zumpe, MaxiJuettner, MadlenTroschke-Meurer, SaschaLoibner, HansSiebert, Nikolai
- [32] Randomisation of Relapsed and Refractory High-Risk Neuroblastoma Patients Treated with Long-Term Infusion of Anti-GD2 Antibody Dinutuximab Beta with or Without Subcutaneous Interleukin-2, A SIOPEN StudyPEDIATRIC BLOOD & CANCER, 2019, 66 : S34 - S35Lode, H.Valteau-Couanet, D.Gray, J.Luksch, R.Wieczorek, A.Castel, V.Ash, S.Owens, C.Laureys, G.Papadakis, V.Garaventa, A.Manzitti, C.Siebert, N.Troschke-Meurer, S.Glogova, E.Poetschger, U.Ladenstein, R.
- [33] Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialLANCET ONCOLOGY, 2018, 19 (12): : 1617 - 1629Ladenstein, RuthPoetschger, UlrikeValteau-Couanet, DominiqueLuksch, RobertoCastel, VictoriaYaniv, IsaacLaureys, GenevieveBrock, PenelopeMichon, Jean MarieOwens, CormacTrahair, TobyChan, Godfrey Chi FungRuud, EllenSchroeder, HenrikPopovic, Maja BeckSchreier, GuenterLoibner, HansAmbros, PeterHolmes, KeithCastellani, Maria RitaGaze, Mark N.Garaventa, AlbertoPearson, Andrew D. J.Lode, Holger N.
- [34] Vaccination of high-risk neuroblastoma patients with anti-id antibody ganglidiomab to maintain protective immunity after passive immunotherapy with anti-GD2 antibody ch14.18/CHOJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7Loibner, HansLode, HolgerSiebert, NikolaiTroschke-Meurer, SaschaMutschlechner, Oliver
- [35] COMBINATION MORPHINE AND KETAMINE IN HIGH RISK NEUROBLASTOMA PATIENTS RECEIVING CH14.18/CHO ANTIBODY/IL2 MAXIMISES ANALGESIA, MINIMISES SIDE EFFECTS AND OPTIMISES IMMUNOTHERAPY DELIVERYPEDIATRIC BLOOD & CANCER, 2014, 61 : S218 - S218Patton, G.Reilly, C.Canning, M.Cupples, P.Moores, T.Bell, G.Ronghe, M.Sastry, J.Murphy, D.
- [36] Low CD4&x207a;/CD25&x207a;/CD127&x207b; regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2ONCOIMMUNOLOGY, 2019, 8 (12):Troschke-Meurer, SaschaSiebert, NikolaiMarx, MadlenZumpe, MaxiEhlert, KarolineMutschlechner, OliverLoibner, HansLadenstein, RuthLode, Holger N.
- [37] Neuroblastoma patients with high-affinity FCGR2A,-3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survivalOncoImmunology, 2016, 5 (11):Siebert, NikolaiJensen, ChristianTroschke-Meurer, SaschaZumpe, MaxiJuettner, MadlenEhlert, KarolineKietz, SilkeMueller, InaLode, Holger N.
- [38] Long Term Follow-Up of Treatment with CH14.18/SP2/0 in Children with Metastatic High-Risk Neuroblastoma: Long-Term Toxicity and Quality-Of-LifePEDIATRIC BLOOD & CANCER, 2021, 68 : S86 - S86Flaadt, T.Rehm, J.Simon, T.Hero, B.Ebinger, M.Queudeville, M.Erdmann, F.Grabow, D.Greil, J.Bader, P.Schlegel, P. G.Eyrich, M.Klingebiel, T.Lang, P.Handgretinger, R.
- [39] Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+γδT cellsONCOIMMUNOLOGY, 2016, 5 (01):Fisher, Jonathan P. H.Flutter, BarryWesemann, FlorianFrosch, JenniferRossig, ClaudiaGustafsson, KenthAnderson, John
- [40] Immunotherapy with Anti-GD2 Antibody ch14.18/CHO±IL2 within the HR-NBL1/SIOPEN Trial Improves Outcome of High-Risk Neuroblastoma Patients Compared to Historical ControlsPEDIATRIC BLOOD & CANCER, 2018, 65 : S53 - S54Ladenstein, R.Poetschger, U.Valteau-Couanet, D.Gray, J.Luksch, R.Castel, V.Ash, S.Laureys, G.Owens, C.Trahair, T.Chan, G. C. F.Ruud, E.Schroeder, H.Beck-Popovic, M.Loibner, H.Schreier, G.Ambros, P.Sarnacki, S.Boterberg, T.Lode, H.